Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes  by de Kruif, John et al.
FEBS Letters 399 (1996) 232-236 FEBS 17941 
Biosynthetically lipid-modified human scFv fragments from phage 
display libraries as targeting molecules for immunoliposomes 
John de Kruif ~'*, Gert Storm b, Louis van Bloois b, Ton Logtenberg a 
aDepartment of Immunology, HP F03.821, Utrecht University, P.O. Box 85500, 3508 GA Utrecht, The Netherlands 
bDepartment of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, P.O. Box 80082, 3508 TB Utreeht, The Netherlands 
Received 8 October 1996; revised version received 6 November 1996 
Abstract A human anti-CD22 single chain (sc) Fv antibody 
fragment from a synthetic phage antibody display library was 
biosynthetically lipid-tagged by using Escherichia coli lipoprotein 
sequences. The purified anti-CD22 scFv lipoprotein was incor- 
porated into iiposomes by detergent dilution. Anti-CD22 
immunoliposomes were shown to bind specifically in a dose- 
and time-dependent manner to CD22+ cell lines and CD22+ B- 
lymphocytes present in freshly isolated samples of blood mono- 
nuclear cells. The immunoliposomes were demonstrated to 
accumulate in intracellular compartments. Biosynthetically 
lipid-tagged human scFv antibody fragments isolated from phage 
display libraries may facilitate the construction of immunolipo- 
somes with improved properties. 
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I. Introduction 
Liposomes, spherical self-assembling colloidal particles 
composed of a phospholipid bilayer membrane ncapsulating 
an internal aqueous pace, have potential as carrier systems to 
deliver substances such as drugs, enzymes, DNA and antigens 
to tissues and cells. To attain specific in vivo homing, lipo- 
somes may be coated with monoclonal antibodies recognizing 
epitopes expressed on the target cells. A disadvantage of these 
'immunoliposomes' is their rapid uptake by cells of the reti- 
culoendothelial system (RES), possibly mediated by Fc or 
C3b receptors interacting with the constant region of the anti- 
body molecule [1]. In addition, when applied in humans, im- 
munoliposomes decorated with murine monoclonal antibodies 
may evoke an immune response against he foreign protein, 
resulting in reduced targeting efficacy and enhanced removal 
by cells of the RES. 
Recent progress in antibody engineering and phage display 
technology has revolutionized our abilities to obtain antibody 
fragments of predefined specificities. Large repertoires of sin- 
gle chain (sc) Fv or Fab antibody fragments displayed on 
filamentous bacteriophage particles, in combination with an 
array of versatile phage selection procedures has yielded a 
broad spectrum of antibodies directed against purified and 
prokaryotic and eukaryotic ell-bound antigens [2,3]. Engi- 
neering steps further permit the 'tailoring' of antibody frag- 
ments to meet specific requirements in terms of avidity, phar- 
macokinetic properties and biological effector functions. For 
example, monovalent scFv fragments have been converted to 
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bivalent and bispecific antibodies or produced as antibody- 
toxin fusion proteins [4]. 
Linking of conventional antibodies to liposomes has been 
achieved by chemical lipid modification of the antibodies, fre- 
quently resulting in significant protein loss, decreased activity 
and heterogeneity of the end product in terms of number and 
location of lipid moieties. Recently, a hybridoma-derived lip- 
id-modified anti-phenyloxazolone scFv molecule has been 
produced in E. coli by genetic engineering. Bacterial lipopro- 
tein (LPP) nucleotide sequences were fused to the DNA en- 
coding the scFv antibody leading, upon introduction of the 
constructs into E. coli, to in vivo fatty acylation of the scFv 
fragment. The lipid-modified scFv purified from the bacterial 
membrane retained their binding activity and, upon simple 
removal of detergent, were shown to spontaneously, stably 
and quantitatively associate with liposomes in an oriented 
manner [5,6]. 
We have initiated experiments o investigate the application 
of phage display library-derived human scFv fragments in 
cell-specific targeting of liposomes. The DNA encoding a hu- 
man CD22-specific scFv fragment from a large synthetic 
phage display library was fused to the E. coli LPP sequence 
and a hexahistidyl tag was added to facilitate purification of 
the modified antibody fragments. Purified scFv fragments 
were incorporated into immunoliposomes and specificity, 
binding kinetics and internalization properties were examined 
using cell lines and freshly isolated hematopoietic cells. The 
results show that lipid-modified human scFv antibody frag- 
ments from phage display libraries can be efficiently and sta- 
bly incorporated into immunoliposomes. The resulting immu- 
noliposomes pecifically interact with target cells expressing 
the correct antigen. These experiments set the stage for the 
production of homogeneous preparations of potentially less 
immunogenic mmunoliposomes for human therapy. 
2. Materials and methods 
2.1. scfv fragments 
The anti-IgG and anti-CD22 scFv fragments were selected from a 
semi-synthetic antibody phage display library constructed in phage- 
mid pHENI. Library construction and isolation of both clones have 
been described in detail elsewhere [2,7]. 
2.2. Oligonucleotides u ed for cloning 
lppfor: 5' gat tac gcc aag ctt gca tgc aaa ttc tat ttc aag gag aca gtc 
ata atg aaa gct act aaa ctg gta ctg ggc. lppbac: 5' ctg cac ctg ggc cat 
ggc ctg arc gat ttt agc gtt gct gga gc. henhis: 5' caa acg aat gga tcc tca 
gtg gtg gtg gtg gtg gtg att cag atc ctc ttc tga g 
2.3. Vector construction 
Oligonucleotides lppfor and lppbac were used to append correct 
restriction sites to the E. coli LPP sequence. Template consisting of 
plasmid pTXI01 [8] was polymerase chain reaction-amplified (PCR), 
digested with HindIII and NcoI and cloned into vector pHEN1 [9], 
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J esulting in vector pLPHEN. Another PCR reaction was performed to 
~dd a hexahistidinyl encoding sequence; pHENI template was ampli- 
lied using primers M13R and the HIS-tag encoding primer henhis, 
digested with XhoI and BamHI and cloned in vector pLPHEN, result- 
ing in vector pLPscH. NcoI-NotI digests were performed to clone scFv 
uncoding fragments from vector pHEN1 into vector pLPscH. 
.4. Lipoprotein-scFv expression and purification 
Vector pLPscH containing the anti-CD22 or anti-IgG scFv gene 
eere transformed to E. coli strain SF110 F' [7] and plated on TYE 
gar containing the appropriate antibiotics and 5% glucose. Next day, 
ells were scraped from the plates and used to inoculate 200 ml LB 
nedium containing 10 ~tg/ml ampicillin and 0.1% glucose. Cells were 
:town with shaking at 25°C until an OD600 of 0.5 was reached. IPTG 
cas added at a final concentration f I mM and incubation continued 
,vernight. Preparation of lipid-tagged scFv fragments was performed 
ssentially as described [6]. A single IMAC step was performed to 
~urify the scFv lipoproteins from detergent solubilized membranes. 
~'he only major deviations from the cited protocol include washing 
md elution of metal affinity columns in 20 mM HEPES pH 7.4, 0.5 M 
qaC1, 1% n-octyl ]3-D-glucoside (OG) and 10% glycerol containing 
; and 200 mM imidazole, respectively. Purity of the lipoprotein sam- 
)les was visualized by SDS-PAGE followed by a Coomassie Brilliant 
~lue staining. 
?.5. Preparation of immunoliposomes 
The liposomes were composed of egg phosphatidylcholine (EPC), 
:gg phosphatidylglycerol (EPG), cholesterol (Chol) and rhodamine- 
~hosphatidylethanolamine (rhodamine) at a molar ratio of 
10:1:5:0.01. EPC and EPG were gifts from Lipoid K.G., Ludwigsha- 
"en, Germany. Chol and OG were purchased from Sigma, St. Louis, 
5SA, and rhodamine from Avanti Polar Lipids, Alabaster, USA. A 
nixture of the appropriate lipids in ethanol was evaporated to dryness 
~y rotary evaporation at 35°C under reduced pressure. After flushing 
~ith nitrogen, the lipid film was solubilized in 1 ml of 4% OG contain- 
ng 150 ~tg lipid modified scFv. After vortexing in the presence of glass 
9eads, the mixture was diluted 26-fold in 5 min with HEPES buffer 
10 mM HEPES, 135 mM NaCI, pH 7.4). The detergent was removed 
9y collecting the immunoliposomes by ultracentrifugation (300 000 X g 
"or 2 h at 4°C) and resuspension of the pellet in 5 ml of HEPES 
9uffer. The phospholipid (PL) concentration of the final dispersion 
was determined to be 2 lamol/ml [10]. The mean particle size was 
Jetermined by dynamic light scattering at 25°C with a Malvern 
J,700 system (Malvern Ltd., Malvern, UK). Bovine serum albumin 
was added to a final concentration of 1%. Immunoliposomes were 
~tored at 4°C until further use. 
2.6. Binding specificity of anti-CD22 liposomes 
Specificity of anti-CD22 liposomes, and as a control anti-lgG lipo- 
somes, was verified by incubating 2x 105 cells from cell lines BJAB, 
Daudi, APD, BV173 (CD22+ B-lineage cells), Jurkat, K562, U266, 
U937 (cells from various CD22- hematopoietic l neages) or 106 per- 
ipheral blood leukocytes (PBL), prepared as described [2], with 100 [tl 
liposomal stock in a total volume of 500 lal ice-cold PBS-2% BSA 
(PBSB). The mixtures were rotated at 4°C for 1 h and washed once 
in PBSB. PBLs were further incubated in 20 ~tl fluorescein isothiocya- 
nate (FITC)-conjugated CD19 antibody (Becton Dickinson) for 20 
rain and washed again. All cells were resuspended in PBSB and ana- 
lysed in a flow cytometer (Becton Dickinson) at standard settings, 
2. 7. Kinetics of anti-CD22 liposome binding 
Binding kinetics of anti-CD22 liposomes to cell lines B JAB (a 
CD22+ B-cell line) and Jurkat (a CD22- T-cell line) was analysed 
by flow cytometry. 5x 10 `5 cells were mixed with increasing concentra- 
tions of immunoliposomes in a total volume of 500 tll PBSB, the 
mixture was slowly rotated at 4°C for 1 h, washed once in PBSB, 
resuspended in PBSB and analysed by flow cytometry. In a similar 
experiment, the immunoliposome concentration was kept constant at 
200 nmol PL/ml while varying the incubation period. 
2.8. Flow<Ttometric analysis of anti-CD22 liposome internalization 
5X l0 s cells were mixed with 100 ~tl immunoliposomes in a total 
volume of 500 I11 ice-cold RPMI containing 5% fetal calf serum 
(RPMIS). The mixture was slowly rotated at 4°C for 1 h before add- 
ing to 1 ml RPMIS in a CO2 incubator set at 37°C. After 0-120 min, 
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cells were removed from the incubator, washed once in 1 ml ice-cold 
PBS and resuspended in 50 lal ice-cold PBS containing 15 mg/ml 
protease K (Qiagen, Germany). Cells were incubated on ice for 30 
rain, resuspended in 1 ml PBSB and analysed by flow cytometry. 
2.9. Internalization of anti-CD22 liposomes; confocal laser scan 
microscopy 
B JAB cells were mixed with anti-CD22 liposomes in RPMIS and 
incubated at 4°C as described previously. After this, the cells were (A) 
washed only, (B) treated with protease K as described, (C) incubated 
at 37°C for 1 h as described or (D) incubated at 37°C for 1 h before 
incubation with protease K. Thereafter, cells were washed twice in ice- 
cold PBS and mounted on Alcian Blue treated coverslips [11]. The 
coverslips were immersed in 3% glutaraldehyde for 30 min, washed 
once in PBS and fixed to slides. Cells were visualized using a confocal 
laser microscope (Leitz, Germany). 
3. Results 
3.1. Vector construction 
PCR technology was used to construct vector pLPscH, add- 
ing an LPP and hexahistidyl-tag sequence to the 5' and 3' 
end, respectively, of scFv encoding genes (Fig. 1). ScFvs ob- 
tained from phage display libraries constructed with the 
phagemid pHENI  can be directly cloned in this vector by a 
single digestion-ligation step. 
3.2. Expression and purification of lipid-tagged scFv JJ'agments 
The DNA encoding previously isolated scFv antibody frag- 
ments specific for human IgG and the CD22 molecule [2,7] 
were cloned into vector pLPscH and the resulting constructs 
were introduced into E. coli strain SF110 for expression of the 
lipid-modified antibodies. Bacterial membranes were isolated 
by ultracentrifugation a d lipid-modified scFv fragments re- 
leased by extraction in Triton X-100 detergent. Immobil ized 
metal affinity chromatography ( IMAC) of these extracts re- 
peatedly yielded ,~ 1.5 mg lipid-tagged scFv per 1 of bacterial 
culture. Aliquots of the crude bacterial membrane xtract and 
purified lipid-modified anti-CD22 scFv were analyzed by 
SDS-PAGE and Coomassie Brill iant Blue staining of gels 
(Fig. 2, lane 2 and 3, respectively). A single major band of 
the anticipated size (approx. 28 kDa) was observed after 
IMAC purification. 
3.3. Preparation qf immunoliposomes 
The lipid-modified anti-CD22 and anti- IgG scFv fragments 
were coupled to EPC/EPG/Chol  liposomes, containing rhoda- 
mine-PE as a fluorescent bilayer marker, by dilution of mixed 
micelles containing OG, lipid and lipid-modified scFv to a 
level far below the critical micelle concentration of the deter- 
gent. Dynamic light scattering measurements yielded a mean 
particle diameter of approx. 0.15 p,m. Incorporat ion of scFv 
molecules in the liposomes was verified by SDS-PAGE fol- 
lowed by Coomassie Brill iant Blue staining (Fig. 2, lane 4). 
Mean immunol iposome particle size and immunoreactivity 
did not alter significantly over a 3 month storage period at 
4°C (results not shown). 
w ~_m_ 
Fig. 1. Schematic representation of vector pLPscH containing an 
scFv encoding gene. The lacZ promotor-operator region (P/O), E. 
coli lipoprotein signal sequence (SS-LPP), E. coli lipoprotein N- 
terminal amino acids (LPP), scFv gene (VH-VL), Myc-tag (Myc) 
and hexahistidyl tag (H) are indicated. 
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Fig. 2. Expression and purification of the lipid modified anti-CD22 
scFv fragment and reconstitution into liposomes. Protein samples 
were run on a reducing SDS-PAGE gel and visualized by staining 
with Coomassie Brilliant Blue. 1, lipid modified anti-CD22 scFv ex- 
pressing _!?. coli culture; 2, pelleted bacterial membranes from the 
aforementioned bacteria; 3, IMAC-purified bacterial membrane ex- 
tract; 4, anti-CD22 scFv liposomes. 
3.4. Binding speciJicity of anti-CD22 liposomes 
Binding specificity of the immunoliposomes was initially 
assessed by incubation of rhodamine-labelled liposomes with 
a panel of CD22+ B-cell lines (BJAB, Daudi, APD and 
BVl73) and CD22- cell lines (Jurkat, K562, U266 and 
U937), representing various hematopoietic lineages. The 
anti-CD22 liposomes displayed exclusive binding to all B- 
cell lines. Control anti-IgG scFv immunoliposomes did not 
bind to any of the cell lines. Specificity of binding was further 
evaluated by incubating rhodamine-labeled anti-CD22 lipo- 
somes with freshly isolated peripheral blood leukocytes. Dou- 
ble staining with a FITC labeled anti-CD19 monoclonal anti- 
body was performed to identify the B-lymphocyte target 
population. Flow-cytometric analysis shows specific staining 
of virtually all CD19+ cells in the sample (Fig. 3). The im- 
munoliposomes do not noticeably interact with cells of other 
hematopoietic lineages in the mixture. Note that the rhoda- 
mine signal is weak because the excitation/emission character- 
istics of this fluorochrome are not optimal for analysis on a 
flow cytometer equipped with a 488 nm argon-ion laser. 
3.5. Binding kinetics of anti-CD22 liposomes 
We evaluated the binding kinetics of rhodamine-PE-loaded 
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anti-CD22 scFv immunoliposomes to the human cell lines 
BJAB (CD22+) and Jurkat (CD22-). Both cell lines were 
incubated for 3 h with various concentrations of the liposomes 
and analyzed by flow cytometry (Fig. 4A). The anti-CD22 
scFv immunoliposomes exclusively bound to the BJAB cell 
line in a dose-dependent manner. Saturation of immunolipo- 
some binding was achieved at 200 nmol PL/ml. Under these 
conditions, binding of liposomes to the BJAB cell line is com- 
pleted within 1 h (Fig. 4B). 
3.6. Internalization of anti-CD22 liposomes 
To assess whether anti-CD22 scFv immunoliposomes are 
internalized after binding, flow-cytometric analysis of 
CD22+ BJAB cells and CD22- control Jurkat cells treated 
with rhodamine-labeled immunoliposomes was performed. 
Cells were pre-incubated for 1 h at 4°C with rhodamine-la- 
beled scFv immunoliposomes. After binding of the immuno- 
liposomes, incubation was continued at 37°C to facilitate en- 
docytosis. At various time intervals, cells were treated with 
protease K to remove cell-surface proteins and bound lipo- 
somes from the cells. The remaining rhodamine fluorescence 
residing in the interior of the cell was detected by flow cytom- 
etry (Fig. 5). Results show a time-dependent intracellular 
accumulation of protease K-resistant rhodamine fluorescence 
in BJAB cells incubated with anti-CD22 liposomes at 37°C 
(Fig. 5A) but not in BJAB cells incubated with control anti- 
IgG liposomes (Fig. 5B). Also, no accumulation of fluores- 
cence was seen in control CD22- Jurkat cells incubated with 
anti-CD22 liposomes, consistent with their inability to bind 
these immunoliposomes (Fig. 5C). Internalisation was already 
apparent 15 min after transfer of cells to 37°C. 
Intracellular localisation of rhodamine label was confirmed 
by confocal laser scan microscopy. BJAB cells were incubated 
with rhodamine-labeled anti-CD22 liposomes for 1 h at 4°C; 
cells were then either directly exposed to protease K or incu- 
bated at 37°C before digestion with protease K. Cells were 
fixed to slides and visualized by confocal laser scan micro- 
scopy. After incubation for 1 h at 4°C bright fluorescence 
is seen associated with the cell membranes (Fig. 6A); this 
fluorescence could be quantitatively removed by exposing 
the cells to protease K (Fig. 6B). Incubation of anti-CD22 
liposome treated cells at 37°C results in the appearance of 
bright fluorescent granules in the interior of the cells, in addi- 
tion to the membrane-associated staining. After incubation of 
these cells in protease K, only the fluorescent granules inside 
the cells remained (Fig. 6C,D). 
102 103 102 103 101 102 103 
Fig. 3. Binding specificity of anti-CD22 liposomes analysed by flow cytometry. Peripheral blood leukocytes (PBL) were incubated with rhoda- 
mine-PE (FL2) labelled immunoliposomes at 4°C for 1 h, washed and double stained with a CD19 FITC (FLl) conjugated monoclonal anti- 
body. Left: forward/sidescatter pattern of PBL. Middle: PBL stained with anti-CD19 FITC (FLl) only. Right: PBL incubated with anti-CD22 
liposomes (FL2) followed by staining in anti-CD19 FITC (FLI). Lymphocytes identified by their forward/sidescatter profile are depicted in 
black. 
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Fig. 4. Flow-cytometric analysis of anti-CD22 scFv immunolipo- 
some binding kinetics. (A) CD22+ B JAB cells (circles) and CD22 
Jurkat cells (triangles) incubated for 1 h with different concentra- 
tions of rhodamine-PE labelled anti-CD22 liposomes. (B) Anti- 
CD22 scFv irnmunoliposomes, at a concentration of 200 nmol PL/ 
ml, incubated with B JAB cells for various periods of time. MFI, 
mean fluorescence intensity. 
4. Discussion 
Preparation of conventional immunoliposomes is based on 
in vitro chemical modification of antibodies for attachment to 
anchor molecules incorporated into the liposomal surface. 
Problems encountered with these methods include inactivation 
of antibodies and low coupling efficiencies. Immunogenicity of
murine proteins and rapid removal by cells of the RES pose 
additional problems associated with the application of immu- 
noliposomes in human therapy [12]. 
Here, we investigated whether in vivo biosynthetically la- 
beled scFv antibody fragments may represent an improved 
targeting moiety for incorporation into immunoliposomes. 
E. coli LPP sequences were fused to DNA encoding a human 
anti-CD22 scFv fragment previously isolated from a synthetic 
phage display library. A hexahistidyl tag was added to facil- 
itate purification by metal affinity chromatography. Yields of 
up to 1.6 mg/l purified lipoprotein were repeatedly obtained 
from detergent-extracted membrane preparations of E. coli 
cultures in shaker flasks. Higher yields of lipoprotein can 
likely be achieved by high cell density fermentation [13]. 
Anti-CD22 scFv immunoliposomes were shown to bind rap- 
idly and specifically to CD22+ target cell lines. When incu- 
bated with samples of blood leukocytes, the anti-CD22 scFv 
immunoliposomes xclusively bound to the B-lymphocyte tar- 
get population and not to other cells in this heterogeneous 
mixture, indicating that lipid modification and incorporation 
into liposomes did not alter the scFv fragment's binding spe- 
cificity. 
Antibody-bearing immunoliposomes may be internalized at 
greatly varying rates, depending on liposome composition, 
antibody and target receptor [14]. The CD22 receptor is con- 
stitutively internalized and degraded in lysosomes, while bind- 
ing of CD22 antibodies to the receptor enhances CD22 inter- 
nalization without stimulating lysosomal degradation above 
the basal constitutive rate [15]. Flow-cytometric and confocal 
laser microscope analysis demonstrated rapid internalization 
of anti-CD22 scFv immunoliposomes. The marker fluoro- 
chrome concentrated in vesicles located at one side of the cells 
between the lobes of the nucleus, indicative of an active up- 
take of immunoliposomes via the endocytotic pathway. 
Immunoliposomes represent a versatile class of in vivo de- 
livery systems that may be used in a large variety of applica- 
tions [16]. Recent advances in liposome technology permit the 
rational design of vesicles with desired pharmacokinetic prop- 
erties for the selective delivery of drug, genes and bioactive 
substances to sub-cellular compartments. We show that in 
vivo lipid-tagged scFv antibodies from phage display libraries 
represent promising molecules for the construction of immu- 
noliposomes for cellular targeting. We anticipate that the 
small size of these molecules, the absence of an immunoglo- 
bulin constant region and chemical coupling reagents in these 
human antibody fragments will reduce their immunogenicity. 
The availability of large libraries of human scFv fragments 
and the power of phage display and selection techniques will 
further facilitate the construction of immunoliposomes with 
tailor-made properties. 
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Fig. 5. Internalization f rhodamine-PE labeled anti-CD22 scFv im- 
munoliposomes. Cells were incubated for 1 h at 4°C with immunoli- 
posomes to allow binding. After binding, incubation was continued 
at 37°C to facilitate endocytosis. At various time intervals amples 
of cells were treated with protease K and remaining intracellular 
rhodamine fluorescence (FL2) detected by flow cytometry. Each of 
the collections of dots corresponds to a separate flow-cytometry 
profile obtained at the time indicated on the x-axis. (A) B JAB cells 
incubated with anti-CD22 scFv immunoliposomes; (B) BJAB cells 
incubated with control anti-lgG immunoliposomes; (C) Jurkat cells 
incubated with anti-CD22 scFv immunoliposomes; BL, blank cells, 
not incubated with liposomes or protease K; -PK, cells incubated 
for 1 h at 4°C with immunoliposomes but not treated with protease 
K. 
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Fig. 6. Internalization of rhodamine-PE labeled anti-CD22 liposomes monitored by confocal aser scan microscopy. CD22+ B JAB cells were in- 
cubated with anti-CD22 scFv immunoliposomes at 4°C (A). Cells were then directly exposed to protease K digestion to remove cell-surface 
proteins and bound liposomes (B), or incubated at 37°C for 1 h (C) before incubation with protease K (D). 
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